Claims
- 1. A compound of the formula (Ib): wherein A is alkylene which optionally is intercalated by a hetero atom or phenylene, contains an oxo group, and/or has an unsaturated bond; B is hydrogen, alkyl, aralkyl or acyl; R is COOR1, CH2OR2 or CON(R3)R4; R1 is hydrogen or alkyl; R2 is hydrogen or alkyl; R3 and R4 each are independently hydrogen, alkyl, hydroxy or alkylsulfonyl X1 is a single bond, phenylene, naphthylene, thiophenediyl, indolediyl, or oxazolediyl; X2 is a single bond, —N═N—, —N═CH—, —CH═N—, —CH═N—N—, —CH═N—O—, —C═NNHCSNH—, —C═NNHCONH—, —CH═CH—, —CH(OH)—, —C(Cl)═C(Cl)—, —(CH2)n—, ethynylene, —N(R5)—, —N(R51)CO—, —N(R52)SO2—, —N(R53)CON(R54)—, —CON (R55)——SO2N(R56)—, —O—, —S—, —SO—, —SO2—, —CO—, oxadiazolediyl, thiadiazolediyl or tetrazolediyl; X3 is alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclic group, cycloalkyl, cycloalkenyl, thiazolinylidenemethyl, thiazolidinylidenemethyl, —CH═NR6 or —N═C(R7)R8, R5, R51, R52, R53, R54, R55 and R56 each are hydrogen or alkyl; R6 is hydrogen, alkyl, hydroxy, alkyoxy, carbamoyloxy, thiocarbamoyloxy, ureido or thioureido; R7 and R8 each are independently alkyl, alkoxy or aryl; and n is 1 or 2; wherein a cyclic substituent may have one to three substituents selected from the group consisting of nitro, alkoxy, sulfamoyl, substituted- or unsubstituted-amino, acyl, acyloxy, hydroxy, halogen, alkyl, alkynyl, carboxy, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl, mesyloxy, cyano, alkenyloxy, hydroxyalkyl, trifluoromethyl, alkylthio, —N═PPh3, oxo, thioxo, hydroxyimino, alkoxyimino, phenyl and alkylenedioxy, or its salt or hydrate thereof, provided that those wherein X, and X2 are a single bond, and X3 is unsubstituted phenyl, and wherein X1 is a single bond, X2 is —O—, and X3 is benzyl or tert-butyl are excluded.
- 2. The compound of claim 1, its salt or hydrate thereof, wherein:
- 3. The compound of claim 2, its salt or hydrate thereof, wherein R is COOR1.
- 4. The compound of claim 2, its salt or hydrate thereof, wherein X1 is phenylene or thiophenediyl, X2 is a single bond, —N═N—, —CH═CH—, ethynylene, —O—, —S—, —CO—, —CON(R55)—, —N(R51)CO— and X3 is phenyl or thienyl.
- 5. The compound of claim 1, its salt or hydrate thereof, wherein:
- 6. The compound of claim 5, its salt or hydrate thereof, wherein B is hydrogen, both X1 and X2 are a single bond, X3 is thienyl, thiazolyl, thiadiazolyl, isothiazolyl, pyrrolyl, pyridyl, benzofuryl, benzimidazolyl, benzothienyl, dibenzofuryl, dibenzothienyl, quinolyl or indolyl.
- 7. The compound of claim 5, its salt or hydrate thereof, wherein X1 is phenylene, thiophenediyl, indolediyl or oxazolediyl, X2 is a single bond, —N═N—, —CH═CH—, ethynylene, —S—or —O—, and X3 is aryl or a heterocyclic group.
- 8. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
- 9. A method for treating a PGD2-mediated disease comprising administering to a subject in need thereof, a PGD2 antagonist according to claim 1.
- 10. A compound A method according to claim 9 wherein said PGD2-mediated disease is selected from the group consisting of systemic mastocytosis, disorder of systemic mast cell activation, tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, injury due to ischemic reperfusion and inflammation.
- 11. A method according to claim 18 wherein said PGD2-mediated disease is nasal occlusion.
- 12. The compound of claim 1, its salt or hydrate thereof, wherein: A is alkylene which optionally contains oxo group and/or has an unsaturated bond; B is hydrogen, R is COOH or CH2OH; X1 is a single bond; X2 is a single bond; X3 is substituted- or unsubstituted-benzothienyl.
Priority Claims (1)
Number |
Date |
Country |
Kind |
7-154575 |
Jun 1995 |
JP |
|
Parent Case Info
This application is a divisional of application Ser. No. 08/973,983, filed Apr. 22, 1998 pending, which is a National Stage of PCT/JP96/01685, filed Jun. 19, 1996.
US Referenced Citations (7)
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 608 847 |
Jun 1982 |
EP |
0 290 285 |
May 1988 |
EP |
61-49 |
Jan 1986 |
JP |
2-62546 |
Dec 1990 |
JP |
06279395 |
Oct 1994 |
JP |
Non-Patent Literature Citations (2)
Entry |
Kohji Hanasaki et al., “Phorbol Ester-induced Expression of the Common, Low-affinity Binding Site for Primary Prostanoids in Vascular Smooth Muscle Cells,” The Journal of Biological Chemistry, 265(9):4871-4875 (1990), ©The American Society for Biochemistry and Molecular Biology, Inc. |
Kohji Hanasaki et al., “Characterization of Platelet Thromboxane A2/Prostaglandin H2 Receptor by a Novel Thromboxane Receptor Antagonist, [3H]S-145,” Biochemical Pharmacology, 38(12):2007-2017 (1989), ©Pergamon Press plc. |